IAG’s CEO will Give a Keynote Lecture at the 8th World Congress on Immunology
IAG’s CEO is invited to give a keynote lecture at the 8th World Congress on Immunology, London, 11-12 March 2019 titled ‘Precision i/o Clinical Trial: Leveraging Technology to Gain Insight into Treatment Efficacy’.
Dr. Olga Kubassova, industry innovator and proponent of the use of modern technologies and methodologies in clinical development will speak how clinical development paradigm in immunology is changing and what modern technologies can offer in a way to accelerate go / no-go decisions in early trials.
The conference brings together researchers and businesses interested in immunology from around the world; it will host a number of scientific and technical sessions on cutting edge research and latest research innovations in the field of Immunology and biomedical sciences.
Olga’s second talk is titled ‘Three types of artificial intelligence (AI) to impact clinical research in the next 3 years’. It will highlight how integrating multi-parametric imaging such as MRI and novel methodologies for imaging data assessment can impact clinical development of inflammatory arthritis and other auto-immune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Lupus and Inflammatory Bowel Disease.
About the Conference:
Immunology World 2019 will provide the platform to meet global leaders in immunology and relevant fields to hear their research at this exclusive scientific program. The Immunology Conference hosting presentations from editorial board members of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology. Immunology World 2019 Organizing Committee also invites Young investigators at every career stage to submit abstracts reporting their latest scientific findings in oral and poster sessions. https://immunology.cmesociety.com/renowned_speakers
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com